Form 4: ARS Pharmaceuticals CEO Richard Lowenthal Sells Shares Under 10b5-1 Trading Plan

Richard E. Lowenthal, CEO of ARS Pharmaceuticals, executed multiple sales of common stock between March 19 and March 21, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Richard E. Lowenthal, the President and CEO of ARS Pharmaceuticals, sold shares of common stock on March 19 and March 21, 2024.
• The sales were executed under a Rule 10b5-1 trading plan established on March 31, 2023.
• On March 19, 2024, 976 shares were sold at a weighted average price of $9.0273, with prices ranging from $9.01 to $9.09.
• Also on March 19, 2024, 942 shares were sold at a weighted average price of $9.0376, with prices ranging from $9.02 to $9.08.
• On March 21, 2024, 372 shares were sold at $9.00.
• Also on March 21, 2024, 100 shares were sold at $9.00.
• Lowenthal also has indirect ownership through trusts, including the Sarina Tanimoto Charitable Remainder UniTrust and the Lowenthal-Tanimoto Family Trust.
• He disclaims beneficial ownership of shares held by the Sarina Tanimoto Charitable Remainder UniTrust.
• Following these transactions, Lowenthal directly owns 4,126,822 shares of common stock.
• He indirectly owns 1,696,494 shares through the Richard E. Lowenthal Charitable Remainder UniTrust and 3,276,854 shares through his spouse.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to stock sales by an executive. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.

Industry Context

This filing is a routine disclosure of insider trading activity. It is common for executives to utilize 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information.

Stakeholder Impact

• The stock sales by the CEO could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates